Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective

被引：0

作者：

Di Trapani, F. ^{[1
]}

Karnon, J. ^{[2
]}

Kaura, S. ^{[3
]}

机构：

[1] Novartis Pharmaceut, Global Med Affairs Oncol, E Hanover, NJ USA

[2] Univ Sheffield, Sheffield, S Yorkshire, England

[3] Novartis Pharmaceut, E Hanover, NJ USA

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1359-6349(07)70824-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2062

引用

页码：202 / 203

页数：2

共 50 条

[31] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
Gil J.M.
Rubio-Terrés C.
del Castillo-Saiz A.
González P.
Canorea F.
[J]. Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
[32] Cost-effectiveness of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC): A UK National Health Service (NHS) perspective
Benedict, A
[J]. VALUE IN HEALTH, 2004, 7 (03) : 221 - 221
[33] COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1-98 AND ATAC TRIALS: A UK PERSPECTIVE
Karnon, J.
Kaura, S.
[J]. VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
[34] Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
Risebrough, Nancy A.
Verma, Shailendra
Trudeau, Maureen
Mittmann, Nicole
[J]. CANCER, 2007, 110 (03) : 499 - 508
[35] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
Simons, WR
Jones, D
Buzdar, A
[J]. CLINICAL THERAPEUTICS, 2003, 25 (11) : 2972 - 2987
[36] Exemestane in adjuvant treatment of early breast cancer in postmenopausal women: results of a UK cost-effectiveness model
不详
[J]. EJC SUPPLEMENTS, 2006, 4 (02): : 151 - 151
[37] A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE
El Ouagari, K.
Kaura, S.
Karnon, J. D.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A279 - A279
[38] Canadian cost-effectiveness analysis of anastrozole versus tamoxifen in early breast cancer.
Verma, S
Rocchi, A
Cheung, S
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S157 - S157
[39] COST-EFFECTIVENESS ANALYSIS OF AROMATASE INHIBITORS AND TAMOXIFEN AS AN ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY-STAGE HORMONE RECEPTOR POSITIVE BREAST CANCER
Sura, S. D.
Sansgiry, S. S.
[J]. VALUE IN HEALTH, 2012, 15 (04) : A220 - A220
[40] COST-EFFECTIVENESS OF ANASTROZOLE, IN COMPARISON WITH TAMOXIFEN, IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL
Fonseca, Marcelo
Araujo, Gabriela T. B.
Saad, Everardo D.
[J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (04): : 410 - 415

← 1 2 3 4 5 →